Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Chromatin structure plays a central role in the regulation of Epstein-Barr virus (EBV) latency. The histone variant H2A.Z.1 has been implicated in chromatin structures associated with the initiation of transcription and DNA replication. Here, we investigate the functional role of H2AZ.1 in the regulation of EBV chromatin, gene expression, and copy number during latent infection. We found that H2A.Z.1 is highly enriched near EBNA1-binding sites at the origin of plasmid replication () and the transcriptional start site for the EBNA1 gene (Qp), and to a lesser extent with transcriptionally active CTCF binding sites on the EBV genomes in both Mutu I Burkitt lymphoma (BL) and SNU719 EBV-associated gastric carcinoma (EBVaGC) cell lines. RNA-interference depletion of H2A.Z.1 resulted in the reactivation of viral lytic genes (ZTA and EAD) and increased viral DNA copy numbers in both MutuI and SNU719 cells. H2A.Z depletion also led to a decrease in EBNA1 binding to and , on the viral episome as well as on oriP plasmids independently of other viral genes and genomes. H2A.Z.1 depletion also reduced peaks of H3K27ac and H4K20me3 at regulatory elements in the EBV genome. In the cellular genome, H2A.Z.1 colocalized with only a subset of EBNA1 binding sites, and H2A.Z.1 depletion reduced EBNA1 binding to these sites and altered the transcription of genes associated with myc targets and mTORC1 signaling. Taken together, these findings indicate that H2A.Z.1 cooperates with EBNA1 to regulate chromatin structures important for epigenetic programming of the latent episome.IMPORTANCECellular factors that maintain viral latency are of fundamental importance. We have found that the cellular histone variant H2A.Z functions in cooperation with the Epstein-Barr virus (EBV) latency maintenance protein EBNA1 to establish a stable epigenome and prevent lytic cycle reactivation during latency. We show that H2A.Z localizes near EBNA1-binding sites on the viral and host genomes, facilitates EBNA1 binding at these sites, and is required for epigenetic programming of viral episomes. H2A.Z depletion perturbed cMyc and mTORC1 pathways that have been implicated in the control of EBV latency. These findings suggest that H2A.Z is an essential constituent of EBV chromatin required for EBNA1 binding and stable maintenance of EBV latency.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12345143PMC
http://dx.doi.org/10.1128/mbio.00302-25DOI Listing

Publication Analysis

Top Keywords

ebna1 binding
20
ebv latency
16
binding sites
16
histone variant
12
epstein-barr virus
12
ebna1
9
variant h2az
8
cooperates ebna1
8
ebv
8
virus ebv
8

Similar Publications

Targeted delivery and pro-apoptotic efficacy of an Epstein-Barr virus nuclear antigen 1-specific affibody in EBV-infected cells in vitro.

Int J Biol Macromol

September 2025

Institute of Molecular Virology and Immunology, Department of Microbiology and Immunology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China. Electronic address:

Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1) sustains viral latency and drives oncogenesis in EBV-driven malignancies such as nasopharyngeal carcinoma and lymphomas. The dimerization of EBNA1 acts as an indispensable molecular switch governing EBV latency and oncogenesis. Disruption of EBNA1 dimerization is a promising strategy, but existing small-molecule inhibitors lack sufficient specificity.

View Article and Find Full Text PDF

The key carcinogenic factor for nasopharyngeal cancer (NPC) is infection with the Epstein-Barr virus (EBV), significantly contributing to its occurrence and development. Insulin-like growth factor binding protein 2 (IGFBP2), known for its aberrant expression in various cancers, plays a pivotal role in oncogenic networks. Investigating IGFBP2's function and mechanism in EBV-associated NPC was the goal of the current study.

View Article and Find Full Text PDF

Chromatin structure plays a central role in the regulation of Epstein-Barr virus (EBV) latency. The histone variant H2A.Z.

View Article and Find Full Text PDF

Epstein-Barr nuclear antigen 1 (EBNA1) is an attractive therapeutic target for identifying pharmaceutical drug molecules to fight Epstein-Barr virus (EBV) contagion because of its key function in viral reproduction. To find potent EBNA1 inhibitors, the Naturally Occurring Plant-based Anticancer Compound-Activity-Target (NPACT) database, including > 1500 compounds, was filtered utilizing computational approaches. The efficiency of the docking technique used to anticipate the inhibitor-EBNA1 binding pose was initially evaluated based on obtainable experimental data.

View Article and Find Full Text PDF

The Epstein-Barr virus EBNA1 protein binds to G-quadruplexes in its own mRNA hence controlling its expression and immune evasion of the virus.

Nucleic Acids Res

June 2025

Univ Brest; Inserm UMR1078; Etablissement Français du Sang (EFS) Bretagne; CHRU Brest, Hôpital Morvan, Laboratoire de Génétique Moléculaire, 22 avenue Camille Desmoulins, F-29200 Brest, France.

The oncogenic Epstein-Barr virus (EBV) evades the immune system but has an Achilles heel: its genome maintenance protein (GMP) EBNA1, which is essential for viral genome replication, but also highly antigenic. Hence, the virus evolved a mechanism to limit the translation of EBNA1 mRNA to the minimum level which allows EBNA1 to fulfil its essential function while minimizing production of EBNA1-derived antigenic peptides. This mechanism involves the binding of the arginine-glycine-rich (RGG) motif of nucleolin (NCL), a host protein, to RNA G-quadruplexes (rG4) of the viral EBNA1 mRNA.

View Article and Find Full Text PDF